Why Dr. Reddy's Stock Fell 3%: Semaglutide Delay Raises Fresh Concerns | Q1 Results

Dr. Reddy's Laboratories shares came under pressure, falling nearly 3% after uncertainty surrounding its Semaglutide opportunity weighed on investor sentiment. The expected exclusivity benefit has been delayed, impacting near-term growth expectations. Gaurang Shah, Sr. VP, Geojit Investments, believes the company is actively working toward resolving the issue and expects a clearer picture in the coming quarters. He added that the second and third quarters could see improved performance once the resolution is achieved, with earnings and profitability likely to benefit.